Cardiovascular disease (CVD) has overtaken infectious illnesses as the leading cause of
mortality and disability worldwide. The pathology that underpins CVD is atherosclerosis …

Background Hypertension could induce many serious diseases, including damage to
vascular endothelial cells. As a non-coding RNA, long noncoding RNA (lncRNA) has …

RNA-based therapies are a new, rapidly growing class of drugs that until a few years ago
were being used mainly in research in rare diseases. However, the clinical efficacy of …

Abstract Purpose of Review To discuss advances on the RNA-targeted therapies to treat
dyslipidemia with the aim of reducing atherosclerotic cardiovascular disease (ASCVD) …

HYPERTENSION is a complex pathophysiological state primarily expressed as chronic high
blood pressure (BP). If unchecked and uncontrolled, it affects major vital organs, including …

Recent advances in RNA interference (RNAi)-based drug development have partially
allowed systemic administration of these agents in vivo with promising therapeutic effects …

Highlights•Hypertension is a major risk factor for cardiovascular and renal
disease.•MicroRNAs are important in the pathogenesis of hypertension.•MicroRNAs provide …

Cardiovascular diseases are the leading cause of death globally and are associated with
increasing financial expenditure. With the availability of next-generation sequencing …

Many RNA species have been identified as important players in the development of chronic
diseases, including cancer. Over the past decade, numerous studies have highlighted how …

Angiotensin II receptor blockers (ARBs) may produce a number of molecule-specific effects
that appear to be independent of interaction with the angiotensin II type 1 (AT 1)-receptor …